CS Genetics
Private Company
Total funding raised: $3.2M
Overview
CS Genetics is a private, pre-revenue platform company pioneering a new approach to single-cell genomics. Its proprietary SimpleCell platform utilizes a novel biochemical method called Kinetic Confinement to perform single-cell indexing in standard labware, eliminating the need for complex microfluidics or proprietary hardware. The company aims to democratize single-cell analysis by reducing cost and complexity, thereby enabling larger-scale studies such as population genomics and accelerating discovery across basic research and drug development.
Technology Platform
SimpleCell platform utilizing Kinetic Confinement, a novel thermodynamic method for single-cell indexing in standard labware, powered by CPair bead reagents.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
CS Genetics competes in the single-cell analysis market dominated by integrated platform providers like 10x Genomics and BD, as well as other hardware-free approaches like those from Parse Biosciences (combinatorial indexing) and others. Its differentiation lies in the novel Kinetic Confinement chemistry promising simplicity and scalability in standard labware.